• Tech News
    • Games
    • Pc & Laptop
    • Mobile Tech
    • Ar & Vr
    • Security
  • Startup
    • Fintech
  • Reviews
  • How To
What's Hot

Elementor #32036

January 24, 2025

The Redmi Note 13 is a bigger downgrade compared to the 5G model than you might think

April 18, 2024

Xiaomi Redmi Watch 4 is a budget smartwatch with a premium look and feel

April 16, 2024
Facebook Twitter Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
Facebook Twitter Instagram Pinterest VKontakte
Behind The ScreenBehind The Screen
  • Tech News
    1. Games
    2. Pc & Laptop
    3. Mobile Tech
    4. Ar & Vr
    5. Security
    6. View All

    Bring Elden Ring to the table with the upcoming board game adaptation

    September 19, 2022

    ONI: Road to be the Mightiest Oni reveals its opening movie

    September 19, 2022

    GTA 6 images and footage allegedly leak

    September 19, 2022

    Wild west adventure Card Cowboy turns cards into weird and silly stories

    September 18, 2022

    7 Reasons Why You Should Study PHP Programming Language

    October 19, 2022

    Logitech MX Master 3S and MX Keys Combo for Business Gen 2 Review

    October 9, 2022

    Lenovo ThinkPad X1 Carbon Gen10 Review

    September 18, 2022

    Lenovo IdeaPad 5i Chromebook, 16-inch+120Hz

    September 3, 2022

    It’s 2023 and Spotify Still Can’t Say When AirPlay 2 Support Will Arrive

    April 4, 2023

    YouTube adds very convenient iPhone homescreen widgets

    October 15, 2022

    Google finishes iOS 16 Lock Screen widgets rollout w/ Maps

    October 14, 2022

    Is Apple actually turning iMessage into AIM or is this sketchy redesign rumor for laughs?

    October 14, 2022

    MeetKai launches AI-powered metaverse, starting with a billboard in Times Square

    August 10, 2022

    The DeanBeat: RP1 simulates putting 4,000 people together in a single metaverse plaza

    August 10, 2022

    Improving the customer experience with virtual and augmented reality

    August 10, 2022

    Why the metaverse won’t fall to Clubhouse’s fate

    August 10, 2022

    How Apple privacy changes have forced social media marketing to evolve

    October 16, 2022

    Microsoft Patch Tuesday October Fixed 85 Vulnerabilities – Latest Hacking News

    October 16, 2022

    Decentralization and KYC compliance: Critical concepts in sovereign policy

    October 15, 2022

    What Thoma Bravo’s latest acquisition reveals about identity management

    October 14, 2022

    What is a Service Robot? The vision of an intelligent service application is possible.

    November 7, 2022

    Tom Brady just chucked another Microsoft Surface tablet

    September 18, 2022

    The best AIO coolers for your PC in 2022

    September 18, 2022

    YC’s Michael Seibel clarifies some misconceptions about the accelerator • DailyTech

    September 18, 2022
  • Startup
    • Fintech
  • Reviews
  • How To
Behind The ScreenBehind The Screen
Home»Startup»Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugs – Startup
Startup

Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugs – Startup

August 11, 2022No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugs – GeekWire
Share
Facebook Twitter LinkedIn Pinterest Email
SEngine CEO and chief scientific officer Carla Grandori. (SEngine Photo)

Seattle startup SEngine Precision Medicine has raised $10 million to propel drug discovery and development and advance its test that tailors drugs to cancer patients.

SEngine cultures patient cancer cells from a biopsy or other material and measures the response to an array of potential therapies using data analytics and computational tools.

The company’s “Paris Test” is designed to assess up to 44 drugs tailored to the cancer type and its genetic features. Oncologists can also request a drug combination study based on the results or order testing of additional drugs. The company has more than 240 candidates in its drug library, covering a broad range of molecular targets.

The Paris Test goes beyond the DNA tests that are increasingly being used by oncologists. Such genomic tests can help identify treatments for 5 to 20% of tumors, depending on cancer type, said SEngine CEO Carla Grandori. But SEngine offers a more direct approach to assessing which drugs are likely to work.

About 75% of Paris Tests yield a drug that the company labels as having an exceptional or good response in cultured cells, said Grandori. It’s designed to work on all types of solid tumors, from breast cancer to pancreatic.

“Just empirically testing a broad range of drugs, we can generally find a solution for a patient,” said Grandori, a former principal investigator at Fred Hutchinson Cancer Center who co-founded the company in 2015. The startup has ongoing collaborations with Fred Hutch, Dana Farber Cancer Institute and others to assess the test.

One aim is to generate data showing the value and effectiveness of the test for insurance companies. About 800 patients have received the test so far, primarily people who were not responding to conventional treatment options.

See also  Seattle biotech startup Ozette lands $26M from Microsoft, Madrona, others to investigate immune cells – Startup
SEngine’s Paris Test to identify treatments for an individual’s tumor. (SEngine Image)

SEngine also leverages the approach to identify new drug candidates. Its model is to take candidates through early testing and regulatory hurdles, licensing them when they are ready for phase 1 clinical trials. The company aims to ready its first candidate next year for a trial.

Several biopharma companies also partnering with SEngine in ongoing drug discovery and development efforts.

Other startups with similar approaches include Duke University spinout Xilis, developing “microorganosphere” tests derived from patient tumors. Kiyatec offers clinical testing for certain brain tumors based on patient cells, and Notable Labs focuses mainly on predicting therapies for blood cancers. 

SEngine assesses a more comprehensive array of drugs and tumor types, said Grandori.

The company has grown from 20 to 30 employees this year and recently launched a clinical trial through the Institute Gustave-Roussy in Paris in patients with colorectal cancer resistant to conventional treatment or with tumor recurrence.

SEngine will use the new cash to fuel drug discovery and help it scale up and market the test, named for the mythological archer Paris who shot Achilles in the heel. The company plans to move from its lab space in Seattle at the Institute for Systems Biology to a larger facility in Bothell, Wash., and invest more in automation and robotics.

Company researchers presented early data on the approach last year at the American Society for Clinical Oncology meeting.

In 38 of 53 patients assessed, company testing could predict their response to drugs. This includes predicting the lack of a response in cases where physicians used a different drug than that suggested by the test. Positive responses accounted for the majority of cases and were measured as tumor shrinkage, improvement in symptoms, or improvements in biomarkers, molecules associated with cancer.

See also  Found Overnight Success? Nine Tips For Scaling Your Business Quickly

Some patient samples yielded low cell counts or had poor viability. But overall, tissue could be generated for testing for about 70% of patients.

One ovarian cancer patient was treated with a drug normally used for lymphoma and leukemia, based on her test results. She left hospice care and two years later is still on treatment guided by the Paris Test. “This is an exceptional case,” cautions Grandori. “But many patients have had from months to years of benefit.”

The funding round was led by the Washington Research Foundation along with Alethea Fulcrum Fund, Vincere Capital Biotech, Bangarang Group, and unnamed investors. Total funding to date is $19 million.



Source link

10M cancer Develop drugs Fred Guide Hutch lands precision spinout Startup test treatment
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Multiple Milestones As New Majority Capital Boosts Entrepreneurship Through Acquisition

September 26, 2023

Getty Images Plunges Into the Generative AI Pool

September 26, 2023

3 Hot Startup Opportunities In Augmented Reality

September 26, 2023

The ChatGPT App Can Now Talk to You—and Look Into Your Life

September 25, 2023
Add A Comment

Comments are closed.

Editors Picks

The next Off-Peak game gets September release date

August 10, 2022

Black Panther: Wakanda Eternally’s first trailer introduces Namor

July 24, 2022

Gene-Edited Yeast Is Taking Over Craft Beer

July 18, 2023

PS5 receives big update with highly requested new feature

September 7, 2022

Subscribe to Updates

Get the latest news and Updates from Behind The Scene about Tech, Startup and more.

Top Post

Elementor #32036

The Redmi Note 13 is a bigger downgrade compared to the 5G model than you might think

Xiaomi Redmi Watch 4 is a budget smartwatch with a premium look and feel

Behind The Screen
Facebook Twitter Instagram Pinterest Vimeo YouTube
  • Contact
  • Privacy Policy
  • Terms & Conditions
© 2025 behindthescreen.uk - All rights reserved.

Type above and press Enter to search. Press Esc to cancel.